Astellas Pharma Inc (ALPMF) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you very much for joining this Q2YTD FY2025 Earnings Call by ASTELUS. I would like to serve as a moderator for today. I'm Chief Communications and IR Officer Kato. Thank you for this opportunity. Today, first of all, we would like to give you the presentation, and after that, we'll have Q&A session. On our website, presentation material is available, and in line with that, we are going to make a presentation. Including Q&A, we will provide you the simultaneous interpretation service between Japanese and English. For simultaneous interpretation service, we are not going to guarantee the accuracy of it. When it comes to the language for this meeting, you can select it from the Zoom webinar screen. And if you select the original, then you can listen to the original voices without hearing the interpretation voices. These are some notes. This material or a presentation by representatives for the company and answers and statements by representatives for the company in the QA session includes forelooking statements based on assumptions and beliefs in light of the information currently available to management as subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors. So please do understand about this. They contain information of pharmaceuticals, including compounds under development, but this information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of these preparations, promote unapproved uses in any fashion, or provide medical advice of any kind. Now I'd like to introduce you participants here. Representative Director, Presenter, CEO, Naoki Okamura. Chief Research and Development Officer, Tadaaki Taniguchi. Chief Commercial and Medical Af...